These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31956005)

  • 1. A symptom combination predicting treatment-resistant schizophrenia - A strategy for real-world clinical practice.
    Ortiz BB; Higuchi CH; Noto C; Joyce DW; Correll CU; Bressan RA; Gadelha A
    Schizophr Res; 2020 Apr; 218():195-200. PubMed ID: 31956005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disorganization domain as a putative predictor of Treatment Resistant Schizophrenia (TRS) diagnosis: A machine learning approach.
    Barone A; De Prisco M; Altavilla B; Avagliano C; Balletta R; Buonaguro EF; Ciccarelli M; D'Ambrosio L; Giordano S; Latte G; Matrone M; Milandri F; Francesco DN; Vellucci L; de Bartolomeis A
    J Psychiatr Res; 2022 Nov; 155():572-578. PubMed ID: 36206601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a few discrete clinical markers may predict categorization of actively symptomatic non-acute schizophrenia patients as treatment resistant or responders: A study by ROC curve analysis and multivariate analyses.
    Iasevoli F; Avagliano C; Altavilla B; Barone A; Ciccarelli M; D'Ambrosio L; Notar Francesco D; Razzino E; Fornaro M; de Bartolomeis A
    Psychiatry Res; 2018 Nov; 269():481-493. PubMed ID: 30195742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia.
    Semiz UB; Cetin M; Basoglu C; Ebrinc S; Uzun O; Herken H; Balibey H; Algul A; Ates A
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1330-6. PubMed ID: 17618026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A four-dimensional model of chronic schizophrenia based on the factorial structure of the Positive and Negative Syndrome Scale (PANSS). A study of a group of 153 chronic schizophrenic patients and comparison with the factorial structure of the BPRS].
    Loas G; Noisette C; Legrand A; Delahousse J
    Encephale; 1997; 23(1):10-8. PubMed ID: 9172962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Symptomatic remission and its relationship to social functioning in Tunisian out-patients with schizophrenia].
    El Gharbi I; Chhoumi M; Mechri A
    Encephale; 2019 Feb; 45(1):15-21. PubMed ID: 29195805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of response to pharmacological treatments in treatment-resistant schizophrenia - A systematic review and meta-analysis.
    Seppälä A; Pylvänäinen J; Lehtiniemi H; Hirvonen N; Corripio I; Koponen H; Seppälä J; Ahmed A; Isohanni M; Miettunen J; Jääskeläinen E
    Schizophr Res; 2021 Oct; 236():123-134. PubMed ID: 34496316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors.
    Fleischhacker W; Galderisi S; Laszlovszky I; Szatmári B; Barabássy Á; Acsai K; Szalai E; Harsányi J; Earley W; Patel M; Németh G
    Eur Psychiatry; 2019 May; 58():1-9. PubMed ID: 30738380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can the Positive and Negative Syndrome scale (PANSS) differentiate treatment-resistant from non-treatment-resistant schizophrenia? A factor analytic investigation based on data from the Pattern cohort study.
    Freitas R; Dos Santos B; Altamura C; Bernasconi C; Corral R; Evans J; Malla A; Krebs MO; Nordstroem AL; Zink M; Haro JM; Elkis H
    Psychiatry Res; 2019 Jun; 276():210-217. PubMed ID: 31108345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The critical treatment window of clozapine in treatment-resistant schizophrenia: Secondary analysis of an observational study.
    Yoshimura B; Yada Y; So R; Takaki M; Yamada N
    Psychiatry Res; 2017 Apr; 250():65-70. PubMed ID: 28142068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association between clinical, sociodemographic, familial, and environmental factors and treatment resistance in schizophrenia: A machine-learning-based approach.
    van Hooijdonk CFM; van der Pluijm M; de Vries BM; Cysouw M; Alizadeh BZ; Simons CJP; van Amelsvoort TAMJ; Booij J; Selten JP; de Haan L; Schirmbeck F; van de Giessen E
    Schizophr Res; 2023 Dec; 262():132-141. PubMed ID: 37950936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study.
    Tarumi R; Tsugawa S; Noda Y; Plitman E; Honda S; Matsushita K; Chavez S; Sawada K; Wada M; Matsui M; Fujii S; Miyazaki T; Chakravarty MM; Uchida H; Remington G; Graff-Guerrero A; Mimura M; Nakajima S
    Neuropsychopharmacology; 2020 Mar; 45(4):632-640. PubMed ID: 31842203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient characteristics, burden and pharmacotherapy of treatment-resistant schizophrenia: results from a survey of 204 US psychiatrists.
    Correll CU; Brevig T; Brain C
    BMC Psychiatry; 2019 Nov; 19(1):362. PubMed ID: 31727015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment resistant schizophrenia and neurological soft signs may converge on the same pathology: Evidence from explanatory analysis on clinical, psychopathological, and cognitive variables.
    de Bartolomeis A; Prinzivalli E; Callovini G; D'Ambrosio L; Altavilla B; Avagliano C; Iasevoli F
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():356-366. PubMed ID: 28887181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations.
    Llorca PM; Lancon C; Disdier B; Farisse J; Sapin C; Auquier P
    J Psychiatry Neurosci; 2002 Jan; 27(1):30-7. PubMed ID: 11836974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis.
    Siskind D; Orr S; Sinha S; Yu O; Brijball B; Warren N; MacCabe JH; Smart SE; Kisely S
    Br J Psychiatry; 2022 Mar; 220(3):115-120. PubMed ID: 35049446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study.
    Bioque M; Parellada E; García-Rizo C; Amoretti S; Fortea A; Oriolo G; Palau P; Boix-Quintana E; Safont G; Bernardo M
    Eur Psychiatry; 2020 Jul; 63(1):e71. PubMed ID: 32669145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis.
    Mizuno Y; McCutcheon RA; Brugger SP; Howes OD
    Neuropsychopharmacology; 2020 Mar; 45(4):622-631. PubMed ID: 31766049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis of the positive and Negative Syndrome Scale (PANSS) factor structure.
    Shafer A; Dazzi F
    J Psychiatr Res; 2019 Aug; 115():113-120. PubMed ID: 31128501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of an algorithm-based definition of treatment resistance in patients with schizophrenia.
    Ajnakina O; Horsdal HT; Lally J; MacCabe JH; Murray RM; Gasse C; Wimberley T
    Schizophr Res; 2018 Jul; 197():294-297. PubMed ID: 29472163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.